Pre-treatment neutrophil-lymphocyte and monocyte-lymphocyte ratios give clues about response, survival, and recurrence in diffuse large B-cell lymphoma

Abstract

Background: Diffuse large B cell lymphoma is a heterogeneous tumor group consisting of large and transformed B cells that makeup 30-40% of all non-Hodgkin lymphoma. Numerous studies point out that initial parameters and post-treatment responses can be used as prognostic factors. We aimed to examine the relationship between diagnosis, clinical and laboratory parameters, treatment response and survival using neutrophil-lymphocyte and monocyte-lymphocyte ratios. Methods: A total of 80 patients, followed in our hematology clinic between January 2009-2019, were included in the study and were analyzed retrospectively. Results: The median value of neutrophil- lymphocyte ratio was 3.5 (0.3-50.2) and of monocyte/lymphocyte ratio was 0.3 (0.1-4.8). In the group with neutrophil-lymphocyte ratio ? 3.5 response rates was significantly lower and exitus rate and the bulky mass presence were significantly higher compared to the group with > 3.5 values (p < 0.05). In the group with monocyte-lymphocyte ratio ? 0.30, the exitus rate was significantly higher compared to group with < 0.30 values (p < 0.05). Conclusion: A statistically significant bulky mass presence was demonstrated in the population above the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio cut off. Although not considered to be sufficient alone, these parameters could be used as prognostic factors in combination with current scoring systems.